Trial register facet
Trial records reported in 2022
29 records with a recorded report or completion year of 2022.
Showing 0 records on this page
Records
29 documents · page 1 of 2
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| CELIAC-PH3-CEDLARA | Larazotide acetate | Phase 3 | Terminated | Randomised, double-blind, placebo-controlled | — | 2022 | Not rated |
| CELIAC-PH3-CEDLARA-BODY-COMPprogramme record | Larazotide acetate | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| CELIAC-PH3-CEDLARA-REGIONAL-JPprogramme record | Larazotide acetate | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3 | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 218 | 2022 | Moderate |
| MMPOWER-3-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Observational | — | 2022 | Very low |
| MMPOWER-3-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3-OLEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| STEP-5 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 304 | 2022 | High |
| STEP-5-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| STEP-5-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 338 | 2022 | High |
| STEP-8-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| STEP-8-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| STEP-8-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-TEENS | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 201 | 2022 | Moderate |
| STEP-TEENS-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| STEP-TEENS-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-TEENS-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| SURMOUNT-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,539 | 2022 | High |
| SURMOUNT-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
page 1 of 2